📌 Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling👉🏻Established a method for long-term expansion of MBCP-derived CTCs from multiple liquid biopsy sources.  
👉🏻Identified NRG1 as a key factor promoting HER3+ CTC survival and metastatic growth.  
👉🏻Uncovered FGFR1 signaling as a compensatory mechanism sustaining CTC survival in the absence of NRG1.  
👉🏻Provided functional data showing that combinatorial blockade of NRG1 and FGFR1 signaling could efficiently target CTCs in MBCPs.
➡️ The dynamic interplay between NRG1–HER3 and FGFR1 signaling reveals the molecular basis of cancer cell plasticity and clinically relevant strategies to target it. This CTC organoid platform enables the identification and validation of patient-specific vulnerabilities and represents an innovative tool for precision medicine.
@OncoAlert #OncoAlertAF @NatureCancer